In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Grail plans Series B round in excess of $1bn; closes initial tranches

Executive Summary

Molecular diagnostics firm Grail Inc. (founded by Illumina last year) announced plans to raise at least $1bn through a Series B round from undisclosed private and strategic investors. The round is expected to close by the end of the first quarter. Proceeds will support development of the company's first blood-based cancer diagnostics, and will also be used to repurchase a portion of Illumina's stake. Following the transaction, Illumina will only own less than 20%, and instead of being a division, Grail will become one of Illumina's largest sequencing customers.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies